Carbamazepine Extended-Release Tablets recall in Canada: product safety
In plain language
This recall involves USA-authorized Carbamazepine Extended-Release Tablets, USP 200 mg and 400 mg, imported into Canada. It's being recalled because there are differences in formulation and physical appearance compared to the Canadian product, and its bioequivalence is unconfirmed. Consumers should contact their healthcare professional for more information.
What to do
- Contact your healthcare professional for more information.
- Discuss any questions or concerns with your healthcare professional.
- Continue to inform your healthcare professional if you experience any side effects.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
Specific affected products are listed in the official notice.
Why this matters
Product safety due to unconfirmed bioequivalence and formulation differences
Do I have this product?
This recall applies to specific products. Details are listed in the official notice.
Frequently Asked Questions
Why was this product recalled?
Product safety due to unconfirmed bioequivalence and formulation differences
What should consumers do?
Contact your healthcare professional for more information. Discuss any questions or concerns with your healthcare professional. Continue to inform your healthcare professional if you experience any side effects.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Product safety due to unconfirmed bioequivalence and formulation differences
When was this product recalled?
This product was recalled on June 5, 2024.